Does the media favor PRQR or TCRX?

In the previous week, ProQR Therapeutics had 1 more articles in the media than TScan Therapeutics. MarketBeat recorded 2 mentions for ProQR Therapeutics and 1 mentions for TScan Therapeutics. ProQR Therapeutics' average media sentiment score of 0.51 beat TScan Therapeutics' score of 0.00 indicating that ProQR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TScan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TCRX or PLX?

In the previous week, TScan Therapeutics and TScan Therapeutics both had 1 articles in the media. Protalix BioTherapeutics' average media sentiment score of 1.49 beat TScan Therapeutics' score of 0.00 indicating that Protalix BioTherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protalix BioTherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TCRX or DTIL?

In the previous week, Precision BioSciences had 18 more articles in the media than TScan Therapeutics. MarketBeat recorded 19 mentions for Precision BioSciences and 1 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 0.00 beat Precision BioSciences' score of -0.16 indicating that TScan Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precision BioSciences 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor VYGR or TCRX?

In the previous week, Voyager Therapeutics had 6 more articles in the media than TScan Therapeutics. MarketBeat recorded 7 mentions for Voyager Therapeutics and 1 mentions for TScan Therapeutics. Voyager Therapeutics' average media sentiment score of 0.14 beat TScan Therapeutics' score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral TScan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

TScan Therapeutics (TCRX) Competitors

$0.77 -0.03 (-3.67%)

As of 04:00 PM Eastern

Compare

TCRX vs. NBP, PRQR, PLX, DTIL, and VYGR

Should you buy TScan Therapeutics stock or one of its competitors? TScan Therapeutics's main competitors and comparable companies include I-Mab (NBP), ProQR Therapeutics (PRQR), Protalix BioTherapeutics (PLX), Precision BioSciences (DTIL), and Voyager Therapeutics (VYGR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does TScan Therapeutics compare to I-Mab?

TScan Therapeutics (NASDAQ:TCRX) and I-Mab (NASDAQ:NBP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

I-Mab has lower revenue, but higher earnings than TScan Therapeutics. I-Mab is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	4.86	-$129.77M	-$0.96	N/A
I-Mab	$3.89M	52.62	-$46.27M	-$0.36	N/A

TScan Therapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, I-Mab has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market.

I-Mab has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. I-Mab's return on equity of 0.00% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%
I-Mab	N/A	N/A	N/A

TScan Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 682.27%. I-Mab has a consensus target price of $9.00, suggesting a potential upside of 408.47%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe TScan Therapeutics is more favorable than I-Mab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, TScan Therapeutics had 1 more articles in the media than I-Mab. MarketBeat recorded 1 mentions for TScan Therapeutics and 0 mentions for I-Mab. TScan Therapeutics' average media sentiment score of 0.00 equaled I-Mab'saverage media sentiment score.

Company	Overall Sentiment
TScan Therapeutics	Neutral
I-Mab	Neutral

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 38.4% of I-Mab shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by insiders. Comparatively, 22.1% of I-Mab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

I-Mab beats TScan Therapeutics on 8 of the 15 factors compared between the two stocks.

How does TScan Therapeutics compare to ProQR Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

ProQR Therapeutics has higher revenue and earnings than TScan Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	10.60	-$47.73M	-$0.50	N/A
TScan Therapeutics	$10.32M	4.86	-$129.77M	-$0.96	N/A

ProQR Therapeutics has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

ProQR Therapeutics presently has a consensus price target of $7.33, suggesting a potential upside of 305.16%. TScan Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 682.27%. Given TScan Therapeutics' higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than ProQR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by insiders. Comparatively, 6.3% of TScan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ProQR Therapeutics has a net margin of -331.33% compared to TScan Therapeutics' net margin of -1,360.61%. ProQR Therapeutics' return on equity of -84.87% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

In the previous week, ProQR Therapeutics had 1 more articles in the media than TScan Therapeutics. MarketBeat recorded 2 mentions for ProQR Therapeutics and 1 mentions for TScan Therapeutics. ProQR Therapeutics' average media sentiment score of 0.51 beat TScan Therapeutics' score of 0.00 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TScan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ProQR Therapeutics beats TScan Therapeutics on 12 of the 16 factors compared between the two stocks.

How does TScan Therapeutics compare to Protalix BioTherapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

TScan Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of 0.02, indicating that its stock price is 98% less volatile than the broader market.

In the previous week, TScan Therapeutics and TScan Therapeutics both had 1 articles in the media. Protalix BioTherapeutics' average media sentiment score of 1.49 beat TScan Therapeutics' score of 0.00 indicating that Protalix BioTherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TScan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protalix BioTherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protalix BioTherapeutics has a net margin of -21.03% compared to TScan Therapeutics' net margin of -1,360.61%. Protalix BioTherapeutics' return on equity of -30.89% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by company insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Protalix BioTherapeutics has higher revenue and earnings than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	4.86	-$129.77M	-$0.96	N/A
Protalix BioTherapeutics	$76.38M	2.62	$8.31M	$0.18	13.78

TScan Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 682.27%. Protalix BioTherapeutics has a consensus price target of $12.00, indicating a potential upside of 383.87%. Given TScan Therapeutics' higher possible upside, research analysts plainly believe TScan Therapeutics is more favorable than Protalix BioTherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Protalix BioTherapeutics beats TScan Therapeutics on 9 of the 15 factors compared between the two stocks.

How does TScan Therapeutics compare to Precision BioSciences?

TScan Therapeutics (NASDAQ:TCRX) and Precision BioSciences (NASDAQ:DTIL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

In the previous week, Precision BioSciences had 18 more articles in the media than TScan Therapeutics. MarketBeat recorded 19 mentions for Precision BioSciences and 1 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 0.00 beat Precision BioSciences' score of -0.16 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TScan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precision BioSciences	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Precision BioSciences has a net margin of -96.73% compared to TScan Therapeutics' net margin of -1,360.61%. Precision BioSciences' return on equity of -72.52% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%
Precision BioSciences	-96.73%	-72.52%	-32.25%

TScan Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 682.27%. Precision BioSciences has a consensus price target of $32.25, suggesting a potential upside of 332.31%. Given TScan Therapeutics' higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Precision BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by insiders. Comparatively, 2.7% of Precision BioSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Precision BioSciences has higher revenue and earnings than TScan Therapeutics. Precision BioSciences is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	4.86	-$129.77M	-$0.96	N/A
Precision BioSciences	$34.26M	6.01	-$45.72M	-$2.80	N/A

TScan Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

Summary

Precision BioSciences beats TScan Therapeutics on 10 of the 16 factors compared between the two stocks.

How does TScan Therapeutics compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Voyager Therapeutics had 6 more articles in the media than TScan Therapeutics. MarketBeat recorded 7 mentions for Voyager Therapeutics and 1 mentions for TScan Therapeutics. Voyager Therapeutics' average media sentiment score of 0.14 beat TScan Therapeutics' score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
TScan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Voyager Therapeutics has higher revenue and earnings than TScan Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	4.74	-$119.72M	-$1.80	N/A
TScan Therapeutics	$10.32M	4.86	-$129.77M	-$0.96	N/A

Voyager Therapeutics presently has a consensus target price of $16.50, indicating a potential upside of 420.50%. TScan Therapeutics has a consensus target price of $6.00, indicating a potential upside of 682.27%. Given TScan Therapeutics' higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Voyager Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Voyager Therapeutics has a net margin of -312.63% compared to TScan Therapeutics' net margin of -1,360.61%. Voyager Therapeutics' return on equity of -54.82% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-312.63%	-54.82%	-42.53%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

Voyager Therapeutics has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Summary

Voyager Therapeutics beats TScan Therapeutics on 11 of the 17 factors compared between the two stocks.

Get TScan Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TCRX vs. The Competition

Export

Metric	TScan Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$50.12M	$3.72B	$7.06B	$12.95B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-0.80	9.13	269.75	24.73
Price / Sales	4.86	1,274.20	652.34	108.63
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	0.36	17.66	11.27	6.42
Net Income	-$129.77M	-$13.25M	$3.45B	$347.12M
7 Day Performance	6.03%	5.36%	3.56%	2.48%
1 Month Performance	-29.63%	-1.74%	-0.58%	-1.04%
1 Year Performance	-53.23%	61.36%	77.52%	23.22%

TScan Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TCRX TScan Therapeutics	2.5034 of 5 stars	$0.77 -3.7%	$6.00 +682.3%	-51.5%	$50.12M	$10.32M	N/A	100	News Coverage Upcoming Earnings
NBP I-Mab	1.9882 of 5 stars	$1.66 +2.8%	$9.00 +443.8%	N/A	$191.40M	$3.89M	N/A	380
PRQR ProQR Therapeutics	3.981 of 5 stars	$1.79 +4.4%	$7.33 +310.8%	-13.6%	$189.12M	$17.99M	N/A	180
PLX Protalix BioTherapeutics	3.2333 of 5 stars	$2.34 +0.6%	$12.00 +413.9%	+59.7%	$188.14M	$76.38M	N/A	200
DTIL Precision BioSciences	2.3424 of 5 stars	$7.22 +2.3%	$32.25 +346.7%	+71.0%	$186.28M	$34.26M	N/A	200	Earnings Report Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TCRX) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TScan Therapeutics (TCRX) Competitors

TCRX vs. NBP, PRQR, PLX, DTIL, and VYGR

How does TScan Therapeutics compare to I-Mab?

Summary

How does TScan Therapeutics compare to ProQR Therapeutics?

Summary

How does TScan Therapeutics compare to Protalix BioTherapeutics?

Summary

How does TScan Therapeutics compare to Precision BioSciences?

Summary

How does TScan Therapeutics compare to Voyager Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX vs. The Competition

TScan Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TScan Therapeutics (TCRX) Competitors

TCRX vs. NBP, PRQR, PLX, DTIL, and VYGR

How does TScan Therapeutics compare to I-Mab?

Which has preferable valuation & earnings, TCRX or NBP?

Which has more risk and volatility, TCRX or NBP?

Is TCRX or NBP more profitable?

Do analysts recommend TCRX or NBP?

Does the media refer more to TCRX or NBP?

Do insiders and institutionals have more ownership in TCRX or NBP?

Summary

How does TScan Therapeutics compare to ProQR Therapeutics?

Which has stronger earnings & valuation, PRQR or TCRX?

Which has more volatility & risk, PRQR or TCRX?

Do analysts prefer PRQR or TCRX?

Do insiders and institutionals have more ownership in PRQR or TCRX?

Is PRQR or TCRX more profitable?

Does the media favor PRQR or TCRX?

Summary

How does TScan Therapeutics compare to Protalix BioTherapeutics?

Which has more volatility and risk, TCRX or PLX?

Does the media refer more to TCRX or PLX?

Is TCRX or PLX more profitable?

Do institutionals & insiders have more ownership in TCRX or PLX?

Which has better earnings and valuation, TCRX or PLX?

Do analysts rate TCRX or PLX?

Summary

How does TScan Therapeutics compare to Precision BioSciences?

Does the media favor TCRX or DTIL?

Is TCRX or DTIL more profitable?

Do analysts prefer TCRX or DTIL?

Do institutionals & insiders have more ownership in TCRX or DTIL?

Which has higher valuation & earnings, TCRX or DTIL?

Which has more volatility & risk, TCRX or DTIL?

Summary

How does TScan Therapeutics compare to Voyager Therapeutics?

Do institutionals & insiders have more ownership in VYGR or TCRX?

Does the media favor VYGR or TCRX?

Which has better earnings & valuation, VYGR or TCRX?

Do analysts prefer VYGR or TCRX?

Is VYGR or TCRX more profitable?

Which has more risk & volatility, VYGR or TCRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX vs. The Competition

TScan Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools